Reuters/Gary CameronAs scrutiny of high drug prices in the US intensifies, so has the finger pointing about who is to blame. This week, that came in the form of an interview in which an executive at Gilead blamed high prices on pharmacy benefit managers, the companies that help insurance plans determine what drugs they'll cover and how much they'll pay.